Leonard, J., Ladha, A., Faramand, R., Roloff, G., Valtis, Y., Tan, V., Miller, K., Zhang, A., Grunwald, M., Kota, V., Boccucci, J., Ulrickson, M., Al-Darobi, A., Hill, L., Muhsen, I., Sasine, J., Advani, A., Sandhu, K., Reshef, R., Luskin, M., Chen, E., Lin, C., Cassaday, R., Kopmar, N., Solh, M., Lee, C., Bobillo, S. O., Tsai, S., O'Connor, T., Hilal, T., Park, J., Vasu, S., Bezerra, E., O'Dwyer, K., Moore, J., Wang, E., McCauley, R., Majhail, N., Ramakrishnan, A., Mountjoy, L., Malik, S., Battiwalla, M., Shaughnessy, P., Mathews, J., Srinagesh, H., Sutherland, K., Jamy, O., Mohty, R., Kumaran, M., Hoeg, R., Oliai, C., Lill, G., Stock, W., Schwartz, M., Othman, T., Koura, D., Dykes, K., Logan, A., Daunov, M., Byrd, K., Yalniz, F., Bachanova, V., Tracy, S., Grover, P., Connor, M., Yaghmour, G., Gatell, V. I., Jackson, C., Oluwole, O., Dholaria, B., Frey, N., Muffly, L., Shah, B., Aldoss, I. (2025). KMT2Ar, but not other high-risk genetics, adversely impacts outcomes in adult patients with relapsed/refractory (R/R) Philadelphia chromosome negative B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel (Brexu-cel). Blood. https://doi.org/10.1182/blood-2025-3365